iBio (IBIO) Free Cash Flow (2010 - 2026)

iBio (IBIO) has 17 years of Free Cash Flow data on file, last reported at -$6.1 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 96.24% year-over-year to -$6.1 million in Q1 2026; TTM through Mar 2026 was -$22.2 million, a 40.44% decrease from a year earlier, with the FY2025 full-year figure at -$15.3 million, up 18.38% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$6.1 million, down from -$5.8 million in the prior quarter.
• Over the last five years, Free Cash Flow for IBIO reached as high as -$3.1 million in Q1 2025 and fell as low as -$16.4 million in Q3 2022.
• Historically, Free Cash Flow has averaged -$6.4 million across 5 years, with a median of -$5.3 million in 2023.
• Across the five-year window, Free Cash Flow surged 67.51% in 2023 and sank 96.24% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$10.6 million in 2022, then soared by 55.56% to -$4.7 million in 2023, then increased by 17.42% to -$3.9 million in 2024, then tumbled by 47.99% to -$5.8 million in 2025, then dropped by 6.26% to -$6.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$6.1 million in Q1 2026, -$5.8 million in Q4 2025, and -$5.7 million in Q3 2025.